Crohn’s disease (CD) is increasing in incidence and prevalence in Canada. It is diagnosed relatively early in life, and is a life-long burden to those who have it. Numerous risk factors have been associated with the development and exacerbation of CD, but one of the most prevalent modifiable risk factors is smoking; people who smoke have a higher likelihood of developing CD than those who do not smoke. Those who smoke after CD development experience more deleterious events during their disease course compared to those who do not smoke. The health care system does not regularly supply smoking cessation programs for these individuals, nor fund them, even though it has been shown that CD patients have a higher rate of smoking cessation than the general population. Therefore, the goal of this thesis is to assess the cost-effectiveness of funding smoking cessation programs for incidence cases of CD.